Key Note Address by Hope Rugo : Extended Adjuvant Endocrine Therapy in Breast Cancer: At Crossroads
Session 7 : ER+Ve Breast Cancer
Chairpersons :
S D Banavali, Vijaykumar DK
Optimal duration of extended letrozole treatment after 5 years of adjuvant endocrine therapy; results of the randomized phase III IDEAL trial (BOOG 2006-05)
Author: Blok EJ
Conference: 2016 SABCS S1-04
A randomized, double-blinded, placebo-controlled clinical trial to evaluate extended adjuvant endocrine therapy (5 years of letrozole) in postmenopausal women with hormone-receptor positive breast cancer who have completed previous adjuvant endocrine therapy: Initial results of NRG oncology/NSABP B-42
Author: Mamounas EP
Conference: 2016 SABCS S1-05
First results from the multicenter phase III DATA study comparing 3 versus 6 years of anastrozole after 2-3 years of tamoxifen in postmenopausal women with hormone receptor-positive early breast cancer
Author: Tjan-Heijnen VC
Conference: 2016 SABCS S1-03
10-year follow-up and biomarker discovery for adjuvant endocrine therapy; results of the TEAM trial
Author: EJ Blok
Conference: 2016 SABCS PD2-07
Predictors of recurrence during years 5-14 in 46,138 women with ER+ breast cancer allocated 5 years only of endocrine therapy (ET)
Author: Hongchao Pan
Conference: 2016 ASCO Annual Meeting, Abstract 505
Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years
Author: Hurvitz S
Reference: N Engl J Med. 2016 Jul 21;375(3):209-19
Comparison of EndoPredict and EPclin With Oncotype DX Recurrence Score for Prediction of Risk of Distant Recurrence After Endocrine Therapy
Author: J R Buus
Reference: J Natl Cancer Inst. 2016 Jul 10;108(11)
Annual Hazard Rates of Recurrence for Breast Cancer During 24 Years of Follow-Up: Results From the International Breast Cancer Study Group Trials I to V
Author: Colleoni M
Reference: Ann Oncol. 2016 May;27(5):806-12